At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Omnipod Horizon™ Automated Glucose Control Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes
In Brief
A clinical study evaluating Omnipod Horizon™ Automated Glucose Control System for Type 1 Diabetes Mellitus. Completed, enrolled 36 participants across 6 sites.
Detailed Summary
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting and outpatient setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionJan 2020
TodayJul 2026
First PostedNov 25, 2019
Enrollment StartDec 15, 2019
Primary CompletionJan 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.6 years ago
Interventions
Omnipod Horizon™ Automated Glucose Control Systemdevice
The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery